NASDAQ: IVAInventiva Sa Stock
$3.36+0.05 (+1.51%)
Updated Apr 17, 2025
IVA Price
$3.36
Fair Value Price
N/A
Market Cap
$321.43M
52 Week Low
$1.53
52 Week High
$3.90
P/E
-0.98x
P/B
-2.71x
P/S
8.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.36M
Earnings
-$191.89M
Gross Margin
100%
Operating Margin
-645.04%
Profit Margin
-1,251%
Debt to Equity
-2.12
Operating Cash Flow
-$90M
Beta
0.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IVA Overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IVA's potential to beat the market
- IVA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IVA
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important IVA news, forecast changes, insider trades & much more!
IVA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IVA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IVA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
IVA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more IVA due diligence checks available for Premium users.
Valuation
IVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.98x
Industry
-177.72x
Market
27.98x
IVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.71x
Industry
4.05x
IVA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
IVA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IVA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$123.9M
Liabilities
$235.0M
Debt to equity
-2.12
IVA's short-term liabilities ($134.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IVA's short-term assets ($123.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IVA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
IVA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IVA vs Biotech Stocks
Inventiva Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.